Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide 100mg vs 400mg in Refractory/Relapsed Multiple Myeloma
NCT00657488Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2001
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of thalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Dec 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00657488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00657488.